- Home
- PKG vs RPRX Comparison
PKG vs RPRX Comparison
Compare PKG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PKG | RPRX |
|---|---|---|
| Founded | 1867 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 16.2B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PKG | RPRX |
|---|---|---|
| Price | $199.45 | $39.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $233.43 | $46.00 |
| AVG Volume (30 Days) | 739.3K | ★ 4.3M |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.52% | 2.21% |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 9.90 | 1.75 |
| Revenue | ★ $8,771,800,000.00 | $2,349,844,000.00 |
| Revenue This Year | $9.43 | $37.13 |
| Revenue Next Year | $13.27 | $1.48 |
| P/E Ratio | ★ $20.05 | $22.68 |
| Revenue Growth | ★ 7.30 | 3.70 |
| 52 Week Low | $172.72 | $24.05 |
| 52 Week High | $245.87 | $41.24 |
Technical Indicators
Market Signals| Indicator | PKG | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 57.50 |
| Support Level | $191.65 | $39.24 |
| Resistance Level | $205.68 | $40.50 |
| Average True Range (ATR) | 4.48 | 0.91 |
| MACD | 0.28 | -0.08 |
| Stochastic Oscillator | 48.31 | 76.02 |
Price Performance
Historical ComparisonAbout PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.